

U.S. Patent Numbers Connected to SARS-CoV and SARS-CoV-2

7,151,163 – Antiviral treatment for SARS by Sequoia Pharmaceuticals (SP) dated 28-Apr-2003.

7,220,852 – SARS Genome patented by the CDC in 2007.

7,279,327 – Methods of producing recombinant SARS coronaviruses patented by the NIH in 2007.

7,776,521 – SARS-CoV isolated from humans patented by CDC dated 17-Aug-2010

9,193,780 – Amino acid sequences that can be directed against coronavirus envelope proteins patented by Sanofi on 24-Nov-2015. Used in current SARS-CoV-2 antigen testing.

U.S. Patent Application Publications Connected to SARS-CoV and SARS-CoV-2

2007/0116716 A1 - SARS CORONAVIRUS “S” PROTEINS AND USES by Singapore researchers published 24-May-2007.

2021/0246431 A1 - HUMAN BETACORONAVIRUS LINEAGE C AND IDENTIFICATION OF N - TERMINAL DIPEPTIDYL PEPTIDASE AS ITS VIRUS RECEPTOR by Nederland and South Africa Hospitals published 12-Aug-2021.